Short Interest to Follow: It Seems Biostage Incorporated (NASDAQ:BSTG) Will Go Up. Just Reported Less Shorted Shares

November 28, 2016 - By Peter Erickson   ·   0 Comments

Short Interest to Follow: It Seems Biostage Incorporated (NASDAQ:BSTG) Will Go Up. Just Reported Less Shorted Shares

The stock of Biostage Incorporated (NASDAQ:BSTG) registered a decrease of 2.68% in short interest. BSTG’s total short interest was 652,700 shares in November as published by FINRA. Its down 2.68% from 670,700 shares, reported previously. With 54,300 shares average volume, it will take short sellers 12 days to cover their BSTG’s short positions. The short interest to Biostage Incorporated’s float is 4.58%. About 3,117 shares traded hands. Biostage Inc (NASDAQ:BSTG) has declined 52.49% since April 25, 2016 and is downtrending. It has underperformed by 58.50% the S&P500.

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The company has a market cap of $14.53 million. The Firm is engaged in developing bioengineered organ implants based on its Cellframe technology. It currently has negative earnings. The Company’s Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

BSTG Company Profile

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., incorporated on May 3, 2012, is a biotechnology company. The Firm is engaged in developing bioengineered organ implants based on its Cellframe technology. The Company’s Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. The Firm is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. The Company’s Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. The Company’s Cellframe technology platform is used to create organ specific Cellspan implants. The Company’s product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

More notable recent Biostage Inc (NASDAQ:BSTG) news were published by: Prnewswire.com which released: “Biostage Reports 2016 Third Quarter Financial Results and Provides Business Update” on November 10, 2016, also Prnewswire.com with their article: “Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc …” published on March 31, 2016, Prnewswire.com published: “Biostage to Host 2016 Third Quarter Update Conference Call” on November 03, 2016. More interesting news about Biostage Inc (NASDAQ:BSTG) were released by: Prnewswire.com and their article: “Biostage Provides Regulatory Update of Cellspanâ„¢ Esophageal Implant” published on October 06, 2016 as well as Prnewswire.com‘s news article titled: “Biostage Appoints Harout DerSimonian, Ph.D. as Chief Scientific Officer to …” with publication date: July 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>